OCUL Catches Eyes, IMGN, CLLS Rise After ASH Data, Catalyst Ahead For RETA

The following are some of today’s top gainers in the pharma/biotech sector.

1. Reata Pharmaceuticals Inc. (RETA)

Gained 12.64% to close Wednesday’s (Dec.13) trading at $25.22.

News: No news

Pipeline:

The Company’s lead product candidates are Bardoxolone methyl and Omaveloxolone.

Recent event:

On December 11, 2017, the Company revealed interim data from the ongoing phase 1b portion of the REVEAL study.

The REVEAL study is a phase 1b/2 trial to evaluate Omaveloxolone in combination with existing immunotherapies for the treatment of metastatic melanoma.

According to the Company, the ongoing REVEAL trial data suggests that Omaveloxolone may have activity in patients who are refractory to checkpoint inhibitors, which is an emerging and large unmet need.

The dose escalation phase of the study will be continued to identify the optimal dose, and upon completion, the Company will decide the next steps in the clinical development program for Omaveloxolone in melanoma.

Clinical Trials & Near-term catalysts:

— A phase III trial of Bardoxolone methyl in a severe genetic form of chronic kidney disease caused by Alport syndrome is underway. Top line data is expected in the first half of 2019.
— A phase III trial of Bardoxolone methyl for the treatment of pulmonary arterial hypertension, or PAH, associated with connective tissue disease, or CTD-PAH, dubbed CATALYST, is underway. Data from CATALYST are expected to be available during the second half of 2018.
— A phase II trial of Bardoxolone methyl for the treatment of other rare forms of chronic kidney disease, dubbed PHOENIX, is ongoing, with data expected in second half of 2018.
— A registrational trial of Omaveloxolone in Friedrich’s ataxia is underway – with topline expected in the second half of 2019.

2. ImmunoGen Inc. (IMGN)

Gained 12.05% to close Wednesday’s trading at $6.79.

Pipeline:

The Company’s lead product candidate is Mirvetuximab soravtansine, under a phase III trial as a single agent for the treatment of platinum-resistant ovarian cancer, dubbed FORWARD I, and under a phase 1b/2 study as combination regimens for both platinum-resistant and platinum-sensitive ovarian cancer, known as FORWARD II.

Also in the pipeline are IMGN779 and IMGN632.

IMGN779 is under a phase I trial in adult patients with relapsed/refractory CD33-positive Acute Myeloid Leukemia while IMGN632, being developed for hematologic malignancies, is expected to enter into phase I study before the end of the year.

Recent event:

— On December 9, 2017, the…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *